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Abstract 
Purpose: To assess the prescribing patterns of asthma medications in a hospital in Dubai, United Arab 
Emirates (UAE) with regard to the demographic pattern of the population.  
Methods: One hundred fifty four patients, 83 male and 71 female, were randomly selected from the 
outpatient respiratory diseases clinic of a tertiary hospital in Dubai, UAE over a 3-month period. Patients 
were asked to complete a structured questionnaire and data were analyzed using STATA 12 software.  
Results: Most of the patients were within the age range of 0 – 10 years. About 86 % of the patients 
were overweight. Half of the patients were non-smokers while 51 % of them had a family history of 
asthma. About 54 % of the patients received multiple drug therapy of which two-drug combinations were 
widely prescribed (31 %). The most utilized drug classes were short acting β-agonists (42 %), xanthine 
drugs (16 %), leukotriene modifiers (14 %) and oral and intravenous corticosteroids (13 %). Statistical 
significant differences among the age groups (F = 2.33, p = 0.0275) were found.  
Conclusion: Primary prevention to reduce the level of exposure to common risk factors for asthma 
would be a vital step to control the disease. More resources should be channeled into educating 
physicians and patients on rational drug utilization to improve the quality of patients’ care. 
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Drugs play an important role in improving human 
health and promoting well-being if used 
rationally. Drug utilization reviews (DUR) provide 
a powerful tool to assess knowledge and 
awareness of patients and physicians on the 
proper use of medications [1]. DUR is 
increasingly used as a tool for cost containment 
and quality assurance. There are three types of 
DUR reviews which are prospective, concurrent 
and retrospective. DURs help regulators 
implement the appropriate interventions to 
address certain issues in the health care 
systems. Among which is designing educational 
programs to improve prescribing practice and 
developing standard treatment protocols to treat 
specific diseases [2]. 
 
Asthma is a condition in which recurrent attacks 
of breathlessness and wheezing occurred mainly 
due to inflammation of the air passages. During 
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asthma attack, airways are narrowed due to 
swelling of the lining of the passages causing 
reduction of the air flow [3]. In 2013 World Health 
Organization (WHO) estimated that 235 million 
people (3.5 percent of the world's population) 
currently suffer from asthma, and it is considered 
as the most common non-communicable disease 
among children [3]. The report on the global 
burden of asthma estimated that the number of 
disability-adjusted life years (DALYs) lost due to 
asthma was estimated to be around 15 million 
DALYs per year, and accounted for around one 
in every 250 deaths worldwide [4]. In UAE, 
asthma is considered one of the most 
predominant disease with about 8 % to 10 % of 
adults are suffering from asthma [5]. It was also 
reported that about 53 % of children, and 17 % of 
adults were missing school and work, 
respectively, due to asthma [6].  
 
In another study conducted in Abu Dhabi, the 
capital of UAE, it was reported that around 10 % 
of patients had made an emergency room visit 
because of Asthma. The direct cost of treating 
asthma in Abu Dhabi was estimated to be about 
105 million AED a year, with 31 % cost spent on 
medications only [7]. 
 
In the current study we investigated the pattern 
of drug use for asthma medications taking into 
consideration the demographic variations among 
patient population. This is done by conducting 
prescription audits and identifies irrationality in 
drug prescribing. Our main aim is to set 
recommendations for health regulators in order 
to take the appropriate measures to improve 





An observational study was planned to analyze 
the utilization patterns of anti-asthmatic drugs in 
a tertiary hospital in Dubai, UAE. The protocol of 
the study protocol was approved by hospital 
administration to conduct the study in the 
hospital. Two hundred patients visiting the out-
patient respiratory diseases clinics were 
randomly selected during a period of three 
months (September to December 2012). Patients 
seen in the specialized clinics are followed up by 
respiratory diseases specialists or consultants. 
Data were collected through a structured 
questionnaire targeted asthmatic patients. The 
questionnaire was composed of two sections; the 
first set of questions were concerning patient 
demographic data i.e. age sex, occupation, level 
of education, family history and smoking status. 
The second set of questions captured all relevant 
information related to the prescribed medications 





Patients diagnosed with asthma and are 
currently on anti-asthmatic medications were 




Asthmatic patients who suffered from other 
diseases such as hypertension, diabetes, heart 
problems, bronchitis, chronic obstructive 
pulmonary disease (COPD), peptic ulcer, 
diabetes mellitus or any other co-morbidities 
were excluded. 
 
Patients were randomly recruited in the study 
and they signed the informed consent form to 
indicate their participation in the study. They 
were interviewed and necessary information was 
collected as per the structured questionnaire. 
The prescriptions of participated patients 
diagnosed with asthma were collected and were 
interviewed for different parameters. 
 
Statistical analysis  
 
Descriptive statistics were carried out for all 
assessed parameters and results were 
expressed as frequencies and percentages. The 
data were analyzed for different parameters 
using One-way analysis of variance (ANOVA). P 
< 0.05 was taken to denote statistical 
significance. All statistical analysis was 
conducted using STATA (StataCorp, College 




Demographic characteristics  
 
Among the 200 randomly selected patients, only 
154 patients were eligible to be included in the 
study as per the inclusion criteria. Around 54 % 
of the study population was males with most of 
the patients diagnosed with asthma were within 
the young age group (0-10) years. About 86 % of 
the patients were overweight. Most of the 
patients are well educated with 54.6 % of 
patients have graduate degree. About 23 % of 
patients were UAE nationals and about 77 % 
were expatriates. Patient smoking history was 
assessed and determined to be of equal 
distribution among patients with 51 % of patients 
were none smokers. About 51.3 % of patients 
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 Figure 1: Age and gender distribution of study participants diagnosed with asthma 
 
Table 1: Patients’ demographic data 
 
Demographic information Number (%) 
Age (years)  
0-10  64 (41.6) 
11-20  6 (3.9) 
21-30  12 (7.8) 
31-40 14 (9.1) 
41-50 16 (10.4) 
51-60 13 (8.4) 
61-07 12 (7.8) 
>70 17 (11.0)  
Gender   
Male 83 (53.9) 
Female 71 (46.1) 
Body mass index  
Underweight 5 (3.2) 
Normal 17 (11.1) 
Overweight 132 (85.7) 
Level of education  
<High school 70 (45.5) 
High school 3(1.9) 
Graduate degree 81 (52.6) 
Nationality  
UAE national 36 (23.3) 
Expatriate  118 (76.6) 
Socioeconomic status  
Low 5 (3.2) 
Lower middle 30  (19.4) 
Upper middle 118 (76.6) 
High 1 (0.4) 
Occupation  
Employed worker 19 (12.3) 
Employed non-worker 42 (27.3) 
Not employed 60 (39.0) 
Retired 33 (4.5) 
Smoking History  
Never smoke 80 (51.9) 
Current smoker 49 (31.8) 
Ex-smoker 25 (16.3) 
Family History of Asthma  
Yes 79 (51.3) 
No 44 (28.6) 
Do not know 31 (20.1) 
had a family history of asthma. The majority of 
patients participated in the study (76.6 %) were 
with upper middle socioeconomic status. Table 1 
summarizes patients’ demographic data. 
 
Age-gender distribution of patients 
diagnosed with asthma  
 
To capture the age gender distribution among 
participants, gender data was analyzed for the 
eight age groups. It was found that male group 
were highly distributed within two age groups 
with 46 (72 %) and 9 (56 %) study participants 
aged between (0-10) years and (40-50) years 
respectively. However, the female group was 
highly distributed within two age group with 10 
(77 %) and12 (71 %) of study participants aged 
between (51-60) years and (above 70) years 
respectively. Figure 1, shows age and gender 
distribution of patients with asthma. A statistical 
analysis was done for age- gender distribution 
using (ANOVA) and the results showed a 
significant difference of gender distribution 
among the different age groups with a p- value of 
0.0275. 
 
A total of 83 (54 %) of study participants received 
multiple drug therapy compared to 71 (46 %) of 
participants who received single drug therapy. In 
multiple drug therapy, two-drug combinations 
were widely prescribed 48 (31 %) than 
combinations of three 24 (16 %) or four drugs 11 
(7 %) as shown in Table 2. 
 
The pattern of drug prescription for treating 
asthma at the study showed that short acting β-
agonist (SABA) are the highest prescribed class 
of medications (42 %) followed by xanthines (16 
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%),leukotriene modifiers (14 %) and 
corticosteroids (13 %) as shown in Table 3. 
 




Number of patients (%) 
1  92 (46%) 
2  63 (31%) 
3  33 (16%) 




Table 3: Types of drugs used to treat asthma 
 
Drug type Drug  
utilization  
Short acting beta agonist (SABA) 42 % 
Xanthines 16 % 
Leukotriene Modifiers 14 % 
Oral and IV corticosteroids 13 % 
Inhaled corticosteroids (ICS) 9 % 
Antibiotics 3 % 
Long acting beta agonist (LABA) 2 % 
Combination Inhalers 1 % 
Grand Total 100% 
 
 
         Figure 2: Most commonly used drugs for the treatment of asthma 
 
The most commonly prescribed drug was 
Combivent® which is composed of salbutamol 
and ipratropium bromide with a ratio of 23 % 
followed by Ventolin® (salbutamol, 16 %) and 
Singular® (montelukast, 14 %) as shown in 
Figure 2. Salbutamol or albuterol were chosen as 
the first line drug in the management of asthma 
and were used as required by patients for the 
symptomatic relief of breathlessness and 
wheezing. 
 
The use of all asthma medication classes was 
determined to be significantly different among the 
different age group (F = 2.33, p = 0.0275). The 0 
– 10 years age group showed the highest rate of 
drug utilization (32 %). 
 
Drug utilization was assessed based on gender 
distribution and found to around (47 %) for males 
versus (53 %) for females. There was no 
statistical significant difference among male and 
female patients in terms of utilizations of asthma 




Drug therapy is used to relieve and prevent 
symptoms of asthma and treat exacerbations. 
Results of the study showed that drug classes 
commonly used to treat asthma include short-
acting beta agonists which are used for short-
term symptom relief; xanthine drugs, leukotriene 
modifiers, oral and intravenous corticosteroids 
which are used during episodes of more severe 
asthma; and inhaled corticosteroids and long-
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acting beta agonists, used for symptom 
prevention and disease control. Over the years, 
inhaled corticosteroids have dominated asthma 
treatment [8]. However, medical reports showed 
that the more the asthma patients used inhaled 
steroids, the weaker their bones became, thus 
increasing the risk of osteoporosis [9]. 
 
Most people who are on inhaled corticosteroids 
use them intermittently, even though guidelines 
recommend that these drugs be used regularly 
by those who need them [10]. Most adults also 
use the strongest formulations of inhaled 
corticosteroids, even though less potent 
formulations are often effective and have fewer 
side effects [10]. The results showed that about 
only 9 % of patients use inhaled corticosteroids, 
which is a good sign of rational drug utilization. 
 
Another therapeutic category used for the 
management of asthma is leukotriene modifiers 
with 14 % of study participants on the treatment 
alone or in combination with other medications. 
The ability of leukotriene receptor antagonist-
based medication, to be used along with inhaled 
beta-agonists or added to existing asthma 
treatment regimens; allow reduction of a 
concomitant therapy. Innovative drugs are the 
leukotriene receptor antagonists which are 
playing an important role in asthma therapy and 
offer advantages over other currently available 
treatments, including excellent tolerability, oral 
route of administration, once-daily dosage and 
proven efficacy in a wide range of patients, 
including children.  
 
The use of short acting drug relievers alone was 
evidenced not to control asthma properly. People 
with asthma who rely on short-acting beta 
agonists, without using inhaled corticosteroids, 
have been shown to be more likely to suffer 
exacerbations or attacks of asthma requiring an 
emergency department visit or an admission to 
hospital [11]. In our study most of study 
participants received salbutamol. Salbutamol is 
the preferred Short acting beta-2 agonist 
because it has an excellent safety profile. Rapid 
reversal of airflow obstruction is best achieved by 
repetitive administration of salbutamol 
nebulisation which is considered to be the first 
medication of choice and it is lifesaving.  
 
Utilization of asthma medication was highest in 
early childhood from the age range of (0-10 
years) and late in elderly (over 70 years). This 
might be due the fact that elderly are especially 
prone to the adverse health effects of chronic 
obstructive pulmonary disease (COPD), which is 
a common disorder in that population [12]. 
 
Limitations of the study 
 
The study was conducted in one hospital only. 
Expanding the study to different settings is 
needed to assess prescribing practices in those 
settings. Assessment of illness severity was not 
possible due to lack of access to patient medical 
records. Thus, patients could not be classified 
into different groups based on severity and could 
not evaluate whether the prescribing patterns 
were in line with international standards. In 
addition, the effect of data based on only one 
visit to a patient in outpatient settings on the 
assessment of how prescribing patterns changed 





Asthma creates substantial burden to individuals 
and families and often restricts individuals’ 
activities for a lifetime. 
 
The present prescribing practice in the 
management of asthma in the setting of this 
study is not sufficiently rational. The presented 
data should be considered a baseline for the 
current practice and may be used in proposing 
appropriate interventions to improve current 
prescribing trend for a more rational utilization of 
asthma medications. It is also recommended that 
to develop asthma treatment guidelines and 
monitor physician adherence to such guidelines 
in order to manage asthmatic patients effectively. 
More steps are required to implement regulatory 
and managerial interventions needed to promote 
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